PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.
PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
|Alternate Symbols: ||nNOS|
|PharmGKB Accession Id:||PA252|
|Cytogenetic Location:||chr12 : q24.22 - q24.31|
|GP mRNA Boundary†:||chr12 : 117645947 - 117799607|
|GP Gene Boundary†:||chr12 : 117642947 - 117809607|
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
Doxorubicin Pathway (Cardiomyocyte Cell), Pharmacodynamics
Representation of the candidate genes involved in adverse effects of doxorubicin in a stylized cardiomyocyte.
Doxorubicin Pathway, Pharmacokinetics
Diagrammatic representation of the transport and metabolism of doxorubicin.
Ibuprofen Pathway, Pharmacodynamics
Stylized cell depicting the mechanism of action of ibuprofen (IBU).
Links to non-PharmGKB pathways.
Publications related to NOS1: 6
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]
||Pharmacogenetics of erectile dysfunction: navigating into uncharted waters. Pharmacogenomics. 2014. Lacchini Riccardo, et al.|
||Individualizing fetal hemoglobin augmenting therapy for beta-type hemoglobinopathies patients. Pharmacogenomics. 2014. Gravia Aikaterini, et al.|
||Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al.|
||Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatric disease and treatment. 2005. Lotrich Francis E, et al.|
||Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation. 2003. Pacher Pál, et al.|
||Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. The Journal of pharmacology and experimental therapeutics. 2000. Weinstein D M, et al.|